BMS's PD-1 mono-antiOpdivo, FDA approved for late esophageal squamous cell carcinoma
Last Update: 2020-06-16
Search more information of high quality chemicals, good prices and reliable suppliers, visit
Bristol Myers Squibb incannounced that the FDA has approved its PD-1 monoanti-Opivo (nivolumab) for patients with progressive, recurrent or metastatic esophagus squamous cell carcinoma (ESCC) who were previously unable to remove diseases after fluororide and platinum chemotherapyThe company noted that Opdivo is the first immunotherapy to treat the disease regardless of the level of tumor PD-L1 expressionThe approval was based on the results of the phase III ATTRACTION-3 trial, in which Opdivo's overall survival (OS) was superior to sequoia chemotherapyThe results showed that Opdivo had a median OS of 10.9 months, while the median OS for Dosi eyew or yew alcohol was 8.4 monthsLast July, the FDA approved Merck's PD-1 monoanti-Keytruda (pembrolizumab) for the treatment of recurrent esophagus localized late or metastatic squamous cell carcinoma, but required patients to have a tumor expression PD-L1 with a comprehensive positive score (CPS) of at least 10, and to develop disease progression after previous treatments in one or more of the body
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.